Nice Insight conducted seven annual studies to survey the pharma landscape and measure what buyers in the market want. These surveys were deployed to respondents in the diverse and dynamic sectors of CDMO, CRO, Equipment, Intermediate, Excipient, Private Equity Venture Capital and Supply Chain.

That being said, each space has winners and losers. Respondents to the study ranked companies on key drivers, including Quality, Reliability, Affordability, Productivity, Innovation and Regulatory. The best of the best in a wide range of categories are honored here, with commentary from key players on what it means to be in the Top 5 for 2017.

Pete Stevenson, Vice President and General Manager, Pfizer CentreOne 
This really is a great honor for our people at Pfizer CentreOne and for the relationships we’ve built with our biopharma partners over the years. We’re proud of the quality and technology we can offer on a global scale. On a personal level, trust is just as important: genuine trust on both sides. Drug development can be a rough road with lots of twists and turns. Trusting relationships make that journey possible.

Janice L. Graff, Director of Finished Product Sales & Business Development, Americas, GSK 
GSK Contract Manufacturing is delighted that our extensive expertise helps our clients deliver products for their patients and customers. We offer the Pharma/Biopharma industry a fully integrated supply chain solution with FDA- and EMA-approved multiproduct facilities. We also provide multiple services for Consumer/OTC products. GSK works with both small-molecule APIs and large molecules, offering development services and site capacity that is suitable for finishing in multiple formats.

By evaluating our customers’ specific needs — from development through commercial production — and matching them with our capabilities and facilities, we ensure successful tech transfer at any stage. We look forward to more successful collaborations in the future.

Peter Benton, President and COO, Worldwide Clinical Trials
For many years, Worldwide Clinical Trials and our depth of clinical expertise and breadth of global capabilities has been one of the industry’s best kept secrets. With this 2017 survey ranking, it looks like that secret is getting out and customers who are demanding a better experience and looking for more — proactive insight, dogged determination, rigorous processes and a commitment to getting it right — are taking notice, choosing Worldwide and recognizing what we can do. I’m very proud of this recognition, on behalf of the entire Worldwide Clinical Trials team.

Uwe Harbauer, Member of the Board of Management at Bosch Packaging Technology and Head of the Product Division Pharma, Bosch Systems 
For Bosch, of course, it is an honor to be recognized as one of the leading suppliers of process and pharmaceutical packaging technology worldwide. The U.S. is one of our most important markets and is expected to grow even further in the future. The study validates our commitment to develop and deliver complete packaging and production lines for the pharmaceutical industry and provide corresponding services. Rather than resting on this success, we continue to develop future-proof solutions and create value for our customers: Bosch Packaging Technology is investing significant resources
to understand and to solve pharma-specific tasks and challenges.

Kai Sievert, Director Global Marketing & Innovation, BASF Pharma Solutions
We are honored our industry partners ranked BASF Pharma Solutions a leading solubilizer supplier. Low-solubilization properties have created significant challenges for the pharmaceutical industry, and we are gratified to be recognized for our expertise and products that have helped overcome them. Moving forward, we will continue to work closely with our customers to gain a thorough understanding of their changing needs, and address them by leveraging our unique solubilization platform in combination with insights from our academic and industry partners across the globe.

Geoff Light, President of Healthcare Logistics Strategy, UPS 
UPS is honored to be recognized by survey respondents for its best-in-class service offerings for clinical trials. Improved health outcomes through sophisticated drugs and vaccines start with successful trials, and optimized logistics is an integral component of medical research and development. UPS will continue to make key investments in technology, temperature-control capabilities and customer service to meet the complex demands of healthcare and life-science organizations. And with our recent acquisition of Marken, a patient-centric supply chain innovator in clinical trial logistics, we are working hard toward becoming the global leader in biological specimen transportation.

Nice Insight Annual Market Surveys

Benchmarking
That’s Nice/Nice Insight can provide insights to your marketing presence and known service offering based on industry buyer responses to one of our annual market surveys.

CDMO
+ Annual Study Year 6
+ 702 Respondents
+ 313 Profiles
+ 163 Deep Dive
www.NiceInsightCDMO.com

CRO
+ Annual Study Year 6
+ 608 Respondents
+ 124 Profiles
+ 73 Deep Dive
www.NiceInsightCRO.com

Original Equipment Manufacturers (OEM)
+ Annual Study Year 3
+ 597 Respondents
+ 137 Profiles
+ 90 Deep Dive
www.NiceInsightPharmaEquipment.com

Excipients
+ Annual Study Year 2
+ 541 Respondents
+ 39 Profiles
+ 31 Deep Dive
www.NiceInsightExcipients.com

Clinical Supply Chain Logistics
+ Annual Study Year 1
+ 320 Respondents
+ 22 Profiles
+ 22 Deep Dive
www.NiceInsightLogistics.com

Pharmaceutical Intermediates
+ Annual Study Year 1
+ 545 Respondents
+ 86 Profiles
+ 62 Deep Dive
www.NiceInsightIntermediates.com

Private Equity/Venture Capital
+ Annual Study Year 1
+ 69 Respondents
+ 135 Profiles
www.NiceInsightPEVC.com